Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.
Moderna announced on Dec. 1, 2021, a revised supply agreement with the UK government for the company’s COVID-19 vaccine and possibly authorized booster vaccine candidates as well. Specifically, this supply agreement encompasses up to 60 million doses of Moderna’s COVID-19 vaccine.
In 2022, as many as 29 million doses are expected to be delivered, and up to 31 million doses are expected to be delivered in 2023. The UK government retains a right to increase or decrease its purchases in 2022 and 2023, under to the agreement, by up to 20% above or below the contracted volumes.
“We thank the UK government for their support in this supply agreement for our mRNA COVID-19 vaccine and booster candidates, if approved, in 2022 and 2023,” said Stéphane Bancel, CEO of Moderna, in a company press release. “This agreement reflects the efforts of the UK government to address the ongoing pandemic and builds on our existing collaboration to protect people in the UK.”
Source: Moderna
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.